

County Durham and Darlington Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on **Thursday 7th March 2019**

Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **G-** Second line / alternative green drug
- G+** **Green+ drug** Specialist initiation / recommendation. Can be recommended by a specialist for initiation in primary care; or be initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- A** **Amber drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs
- X** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within County Durham & Darlington.
- ⊘** **Not Reviewed** - Drugs that haven't been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in County Durham & Darlington.
- **Unclassed Drug** - Drugs that do not fall into one of the above categories

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
None				
2) New Requests				
None				
3) New formulations & extensions to use				
None				
5) Products considered by NICE				
TA548: Decitabine for untreated acute myeloid leukaemia (terminated appraisal)		✓		The formulary will reflect the TAG – NHS England is the responsible commissioner – NICE did not recommend use.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA549: Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)		✓		The formulary will reflect the TAG – NHS England is the responsible commissioner – NICE did not recommend use.
TA550: Vandetanib for treating medullary thyroid cancer		✓		The formulary will reflect the TAG – NHS England is the responsible commissioner – NICE did not recommend use.
TA551: Lenvatinib for untreated advanced hepatocellular carcinoma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA555: Regorafenib for previously treated advanced hepatocellular carcinoma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA556: Darvadstrocel for treating complex perianal fistulas in Crohn's disease		✓		The formulary will reflect the TAG – CCG is the responsible commissioner - NICE did not recommend use.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
7) Appeals against earlier decisions by the APC				
None				
8) Products considered by NTAG				
None				
8) Miscellaneous decisions by the APC				
Dipipanone (Diconal®) – add to formulary as NOT APPROVED	✓			Currently Diconal is not listed on the formulary but following a request from ND+DDES CCG was agreed to add as NOT APPROVED as per memo Darlington PCT + Durham PCT from May 2007 which did not recommend use in new patients and that existing patients should be reviewed. Decision: agreed to add to formulary as NOT APPROVED.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Linezolid (oral) – change in RAG status to RED if course >14 days	✓			Currently listed as GREEN+ but courses greater than 14 days require but BNF/SPC states Patients must have weekly bloods taken to monitor for haematological side effects if receiving treatment for more than 10 to 14 days. In those receiving treatment for more than 4 weeks a pre-treatment eye assessment is recommended followed by monthly assessments.states WBC. Decision: change approved
Ranolazine – remove need for specialist to do all titration before transferring to GP.	✓ G+			Cardiology feels this restriction no longer appropriate as GPs to titration for other cardiac drugs, and BNF/SPC gives advice on titration – no special monitoring and adjust according to response (similar to Ivabradine and Nicorandil). Decision: change approved
Vitamin B Co Strong – change from GREEN to RED.	✓ R			Confirmed with dieticians should only be used on an inpatient basis for refeeding syndrome and not to be used for alcohol related disorders Decision: change approved

The following guidelines were presented to and approved at the March 2019 meeting of the APC:

- RMOG Position Statement – Heparinised Saline for Central Line Patency
- County Durham & Darlington Guidelines for Gluten Free Prescribing – updated
- County Durham & Darlington Paediatric Asthma Guidelines

The following Green+ drug information leaflets were presented to and approved at the March 2019 meeting of the APC:

- Nil

The following shared care guidelines were presented to and approved at the March 2019 meeting of the APC:

- Nil

Other documents presented to and approved at the March 2019 meeting of the APC:

- CDDFT Outpatient Treatment Recommendation Form (updated)